- LIVE QUOTES
- LEARN
- HELP
Wall Street JournalEN
The Top 5 Analyst Questions From Bristol-Myers Squibb’s Q1 Earnings Call
Bristol-Myers Squibb’s first quarter results reflected a blend of strong execution in its newer growth portfolio and ongoing pressure from generic competition in legacy products. Management attributed the quarter’s performance to robust uptake in key drugs such as Breyanzi, Reblozyl, and Camzyos, as well as the initial traction from recent launches like Cobenfi and OpdivoCuvanti. CEO Christopher Boerner noted that, despite challenges from generic entries and Medicare Part D changes affecting older products, “our growth portfolio again delivered double-digit sales growth driven primarily by strength in key marketed products.”
Is now the time to buy BMY? Find out in our full research report (it’s free).
Bristol-Myers Squibb (BMY) Q1 CY2025 Highlights:
- Revenue: $11.2 billion vs analyst estimates of $10.78 billion (5.6% year-on-year decline, 3.9% beat)
- Adjusted EPS: $1.80 vs analyst estimates of $1.50 (19.9% beat)
- Adjusted EBITDA: $5.19 billion vs analyst estimates of $3.83 billion (46.3% margin, 35.5% beat)
- The company lifted its revenue guidance for the full year to $46.3 billion at the midpoint from $45.5 billion, a 1.8% increase
- Management raised its full-year Adjusted EPS guidance to $6.85 at the midpoint, a 2.2% increase
- Operating Margin: 29.5%, up from -96.4% in the same quarter last year
- Market Capitalization: $95.32 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions Bristol-Myers Squibb’s Q1 Earnings Call
- Christopher Schott (JPMorgan) asked about the company’s ability to navigate evolving tariff policies and the outlook for Cobenfi after adjunctive trial results. CEO Christopher Boerner explained existing tariff impacts were factored into guidance and emphasized a continued focus on monotherapy for Cobenfi.
- Mohit Bansal (Wells Fargo) inquired about the balance between cost optimization and R&D investment, especially after recent pipeline setbacks. Boerner and Chief Medical Officer Samit Hirawat highlighted ongoing productivity efforts and a robust late-stage pipeline with multiple readouts expected by decade’s end.
- Luisa Hector (Berenberg) questioned whether Cobenfi’s ARISE trial results would affect confidence in upcoming Alzheimer’s psychosis data. Hirawat clarified that differing disease biology and study design mean the ARISE results have no bearing on Alzheimer’s trials.
- Geoffrey Meacham (Citi) focused on the impact of tariffs on supply chains and business development strategy amid low biotech valuations. CFO David Elkins described a flexible global manufacturing network and reaffirmed business development remains the top capital allocation priority.
- Evan Seigerman (BMO Capital) asked about potential effects of international reference pricing and the impact of relaxed cardiac monitoring requirements for Camzyos. Boerner discussed ongoing policy engagement, while Chief Commercialization Officer Adam Lenkowsky noted the label change should accelerate Camzyos uptake.
Catalysts in Upcoming Quarters
In the quarters ahead, our analysts will be closely monitoring (1) the pace of adoption and market penetration for Cobenfi and other recently launched growth products, (2) pivotal clinical trial outcomes for key pipeline assets, particularly in neuroscience and oncology, and (3) realization of cost savings from ongoing productivity initiatives. Progress on business development and regulatory updates will also be important indicators of future performance.
Bristol-Myers Squibb currently trades at $46.88, down from $48.51 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.